绝经激素治疗与结直肠癌风险:瑞典匹配队列研究
结果显示MHT使用者结肠癌和直肠腺癌风险总体降低,尤其40-60岁女性;既往使用雌激素单药者风险降低更明显;替勃龙则增加左侧结直肠腺癌风险。
要点
- MHT使用者结肠癌OR=0.67,直肠腺癌OR=0.66,风险总体降低。
- 既往雌激素单药使用者结肠癌OR=0.49,直肠癌OR=0.36,降低更显著。
- 替勃龙与左侧结直肠腺癌风险增加相关。
核心结论
- MHT使用可能降低结直肠腺癌风险,雌激素单药和雌孕激素联合治疗均可见此关联,既往使用者尤为明显。
主要发现
- 与从未使用者相比,MHT使用者结肠癌OR=0.67(95%CI 0.63-0.72),直肠腺癌OR=0.66(95%CI 0.60-0.73),40-60岁女性中尤为明显。
- 当前使用雌激素单药者结肠癌OR=0.73(95%CI 0.65-0.82),直肠癌OR=0.76(95%CI 0.64-0.90),尤其使用雌二醇和雌三醇时。
- 既往使用雌激素单药者结肠癌OR=0.49(95%CI 0.43-0.56),直肠癌OR=0.36(95%CI 0.28-0.45)。
- 当前使用雌孕激素联合治疗者结肠腺癌OR=0.62(95%CI 0.54-0.72),直肠腺癌OR=0.60(95%CI 0.49-0.74)。
- 替勃龙显示左侧结直肠腺癌风险增加;口服和经皮MHT使用模式相似。
临床怎么用
- 临床评估绝经激素治疗时,可考虑其与结直肠腺癌风险降低的关联,尤其对40-60岁女性及既往雌激素单药使用者。
- 使用替勃龙时需关注左侧结直肠腺癌风险可能增加。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Menopausal hormone therapy (MHT) has been associated with various malignancies. AIMS: To investigate the association of various MHT regimens with the risk of colorectal cancer (CRC). METHODS: All MHT ever-users (n = 290 186) were included through the Swedish Prescribed Drug Registry, with a 1:3 group-level matching to non-users. Ever-users were defined as women who received ≥1 dispensed prescription of systemic MHT during 2005-2012 in Sweden. All CRC cases after drug initiation were extracted from the Swedish Cancer Registry. The association was assessed by multivariable conditional logistic and Cox regression models, presented as odds ratios (ORs) or hazard ratios (HRs) with 95% confidence intervals (CIs) considering different regimens, duration and age at treatment initiation. RESULTS: Compared with non-users, MHT users had an overall reduced odds for colon (OR = 0.67, 95% CI 0.63-0.72) and rectal adenocarcinoma (OR = 0.66, 95% CI 0.60-0.73), especially among women aged 40-60 years. Current users of oestrogen-only preparations (E-MHT) showed a reduced odds (colon OR = 0.73, 95% CI 0.65-0.82; rectal OR = 0.76, 95% CI 0.64-0.90) compared to non-users, particularly with oestradiol and oestriol. Past E-MHT use showed stronger odds reductions (colon OR = 0.49, 95% CI 0.43-0.56; rectal OR = 0.36, 95% CI 0.28-0.45). Current use of oestrogen combined progestin therapy (EP-MHT) indicated a less prominent odds reduction (colon adenocarcinoma OR 0.62, 95% CI 0.54-0.72; rectal adenocarcinoma OR = 0.60, 95% CI 0.49-0.74) than past users. Tibolone showed an increased risk of left-sided colorectal adenocarcinoma. Oral and cutaneous MHT usage showed similar patterns. CONCLUSIONS: MHT use may decrease colorectal adenocarcinoma risk, for both E-MHT and EP-MHT, and especially in past users.
引用
- Liu Q, Simin J, Debelius J, et al. Menopausal hormone therapies and risk of colorectal cancer: a Swedish matched-cohort study. Aliment Pharmacol Ther. 2021. PMID: 33857339. doi:10.1111/apt.16362
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。